EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

Rhian Siân Davies iD, Christian Smith, Gwenllian Edwards, Rachel Butler, Diane Parry, Jason Francis Lester

Lung Cancer International · 2017

DOI: 10.1155/2017/9614938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung Cancer International, 2017. Verfasst von Rhian Siân Davies und 5 weiteren Autor:innen. Beteiligte Einrichtung: Velindre Cancer Centre, Cardiff, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of histological diagnosis.

Methods

The records of 70 patients with advanced adenocarcinoma of the lung managed through a single multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether this was sent for EGFR testing, and the result.

Results

Seventy patients were identified. In 21/25 (84%) cases, cytological sampling was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing was not carried out in 22/70 (31.4%) patients. There was insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other reasons for not testing included poor patient fitness and problems in the diagnostic pathway.

Conclusions

In this series, cytological tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.

Autor:innen und Institutionen

  • Velindre Cancer Centre, Cardiff, UK.
  • Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.
  • University Hospital Llandough, Cardiff, UK.

ORCID-Profile: Rhian Siân Davies

Zitieren

APA

Davies, R. S., Smith, C., Edwards, G., Butler, R., Parry, D., & Lester, J. F. (2017). Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. Lung Cancer International. https://doi.org/10.1155/2017/9614938

Vancouver

Davies RS, Smith C, Edwards G, Butler R, Parry D, Lester JF. Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. Lung Cancer International. 2017. doi:10.1155/2017/9614938

BibTeX
@article{Davies2017,
  author = {Davies, Rhian Siân and Smith, Christian and Edwards, Gwenllian and Butler, Rachel and Parry, Diane and Lester, Jason Francis},
  title = {Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma},
  journal = {Lung Cancer International},
  year = {2017},
  doi = {10.1155/2017/9614938}
}
Kostenlos starten →